Israel’s CollPlant has been awarded the EU CE Mark for VergenixSTR, a soft tissue repair matrix for the treatment of tendinopathy; Hebrew University scientists’ peptide treatment for HIV to make it self-destruct has now been tested on the blood from AIDS patients, and much more.

Israeli biotech Kamada has launched a anti-Rabies vaccine in 10 countries, and Israel’s CollPlant announced positive final trial results for a gel designed for the treatment of chronic, hard to heal wounds and surgical wounds.